Press release
DelveInsight's Ovarian Cancer Pipeline Report Highlights 180+ Industry Trailblazers | Allarity Therapeutics, OSE Immunotherapeutics, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals
Ovarian Cancer Pipeline
DelveInsight's "Ovarian Cancer Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Ovarian Cancer market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging Ovarian Cancer drugs, the Ovarian Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Ovarian Cancer Pipeline Report
• DelveInsight's Ovarian Cancer Pipeline analysis depicts a robust space with 180+ active players working to develop 200+ pipeline drugs for Ovarian Cancer treatment.
• The leading Ovarian Cancer companies include Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-La Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, GlaxoSmithKline (GSK), AbbVie, Eli Lilly, Novartis, Roche, Verastem Oncology, Corcept Therapeutics, AstraZeneca, Genmab, Genelux Corporation, Mural Oncology, Daiichi Sankyo, Merck, Sutro Biopharma, Bristol-Myers Squibb, and others are evaluating their lead assets to improve the Ovarian Cancer treatment landscape.
• Key Ovarian Cancer pipeline therapies in various stages of development include Avutometinib (VS-6766) + Defactinib (VS-6063), Relacorilant (CORT125134), IMFINZI (durvalumab), Rinatabart sesutecan (Rina-S), Olvimulogene nanivacirepvec (Olvi-Vec), Nemvaleukin alfa (ALKS 4230), Catequentinib (anlotinib/AL3818), Raludotatug deruxtecan (R-DXD/DS-6000A), Luveltamab tazevibulin (STRO-002), Sacituzumab tirumotecan, Atezolizumab, Tisotumab Vedotin, SON-1010, and others.
• In March 2025, IMUNON, Inc. announced that the FDA is aligned with the protocol for its Phase 3 pivotal trial, OVATION 3, of its lead candidate IMNN-001 for treating women with newly diagnosed advanced ovarian cancer. The company is initiating trial sites and preparing to enroll participants.
• In February 2025, Gradalis, Inc. announced that the FDA granted RMAT designation for its personalized immunotherapy, Vigil® (Gemogenovatucel-T), based on positive results from the Phase 2b VITAL trial. Vigil is being developed as a maintenance treatment for women with advanced Stage IIIb/IV ovarian cancer who are HRP, have high clonal tumor mutation burden, and are in complete response after surgery and chemotherapy.
• In February 2025, the FDA granted fast-track designation to CUSP06, a CDH6-directed antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant ovarian cancer.
• In January 2025, the FDA accepted and prioritized the review of the new drug application (NDA) for the combination of avutometinib (VS-6766) and defactinib (VS-6063) to treat adult patients with KRAS-mutant recurrent low-grade serous ovarian cancer who have had at least one prior systemic therapy.
• In December 2024, Verastem Oncology announced the FDA's acceptance of its New Drug Application (NDA) for avutometinib, a RAF/MEK clamp, combined with defactinib, a FAK inhibitor, under the accelerated approval pathway for treating KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) in adults after prior systemic therapy.
Request a sample and discover the recent breakthroughs happening in the Ovarian Cancer pipeline landscape @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Ovarian Cancer Overview
Ovarian cancer is the deadliest gynecological cancer and the fifth leading cause of cancer-related deaths in women. Most cases are diagnosed at an advanced stage, leading to poor outcomes. Current screening methods, including CA-125 assays and transvaginal ultrasounds, have shown limited effectiveness in reducing mortality.
Epithelial ovarian cancer has four main histological types: serous, endometrioid, clear cell, and mucinous, with rarer subtypes like Brenner and seromucinous tumors. It is further classified into Type I (low-grade, slow-growing, better prognosis) and Type II (high-grade, aggressive, poor prognosis) tumors. Type II tumors, often linked to p53 mutations, are more advanced at diagnosis and highly proliferative.
Standard treatment includes surgery and platinum-based chemotherapy, with anti-angiogenic bevacizumab and PARP inhibitors gaining traction. However, high recurrence rates and treatment resistance highlight the urgent need for improved early detection and novel targeted therapies.
Find out more about Ovarian Cancer medication @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Ovarian Cancer Treatment Analysis: Drug Profile
Atezolizumab: Genentech
Atezolizumab is a humanized kappa IgG1 monoclonal antibody produced in Chinese hamster 0vary cells. Engineered to eliminate Fc-effector function, it features a single amino acid substitution (asparagine to alanine) at position 298, preventing Fc receptor binding and PD-L1+ cell depletion. By targeting PD-L1, it blocks interactions with PD-1 and B7.1, restoring T-cell activity. Currently, Atezolizumab is in Phase 3 clinical trials for ovarian cancer treatment.
Tisotumab Vedotin: Genmab
Tisotumab vedotin (HuMax-TF, HuMax®-TF-ADC, or TF-011-MMAE) is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein involved in tumor signaling and angiogenesis. It consists of an anti-TF antibody linked to monomethyl auristatin E (MMAE) via a cleavable mc-val-cit-PABC linker. The drug is in Phase 2 clinical trials for ovarian cancer.
SON-1010: Sonnet Biotherapeutics
SON-1010 is a modified version of human IL-12 developed using Sonnet's fully human albumin-binding (FHAB®) platform, designed to enhance tumor microenvironment targeting and extend pharmacokinetics and pharmacodynamics. Sonnet and Roche have partnered to evaluate SON-1010 in combination with atezolizumab for platinum-resistant ovarian cancer (PROC). The drug is currently in Phase I/II development for ovarian cancer.
Key Ovarian Cancer Therapies and Companies
• Avutometinib (VS-6766) + Defactinib (VS-6063): Verastem Oncology
• Relacorilant (CORT125134): Corcept Therapeutics
• IMFINZI (durvalumab): AstraZeneca
• Rinatabart sesutecan (Rina-S): ProfoundBio/Genmab
• Olvimulogene nanivacirepvec (Olvi-Vec): Genelux Corporation
• Nemvaleukin alfa (ALKS 4230): Mural Oncology
• Catequentinib (anlotinib/AL3818): Advenchen Laboratories
• Raludotatug deruxtecan (R-DXD/DS-6000A): Daiichi Sankyo and Merck
• Luveltamab tazevibulin (STRO-002): Sutro Biopharma
• Sacituzumab tirumotecan: Merck and Kelun-Biotech
Learn more about the novel and emerging Ovarian Cancer pipeline therapies @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Ovarian Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Scope of the Ovarian Cancer Pipeline Report
• Coverage: Global
• Key Ovarian Cancer Companies: Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-La Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, GlaxoSmithKline (GSK), AbbVie, Eli Lilly, Novartis, Roche, Verastem Oncology, Corcept Therapeutics, AstraZeneca, Genmab, Genelux Corporation, Mural Oncology, Daiichi Sankyo, Merck, Sutro Biopharma, Bristol-Myers Squibb, and others.
• Key Ovarian Cancer Pipeline Therapies: Avutometinib (VS-6766) + Defactinib (VS-6063), Relacorilant (CORT125134), IMFINZI (durvalumab), Rinatabart sesutecan (Rina-S), Olvimulogene nanivacirepvec (Olvi-Vec), Nemvaleukin alfa (ALKS 4230), Catequentinib (anlotinib/AL3818), Raludotatug deruxtecan (R-DXD/DS-6000A), Luveltamab tazevibulin (STRO-002), Sacituzumab tirumotecan, Atezolizumab, Tisotumab Vedotin, SON-1010, and others.
Dive deep into rich insights for drugs used for Ovarian Cancer treatment; visit @ https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Ovarian Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Ovarian Cancer Pipeline Therapeutics
6. Ovarian Cancer Pipeline: Late-Stage Products (Phase III)
7. Ovarian Cancer Pipeline: Late-Stage Products (Phase III)
8. Ovarian Cancer Pipeline: Mid-Stage Products (Phase II)
9. Ovarian Cancer Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release DelveInsight's Ovarian Cancer Pipeline Report Highlights 180+ Industry Trailblazers | Allarity Therapeutics, OSE Immunotherapeutics, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals here
News-ID: 3942895 • Views: …
More Releases from DelveInsight
Spinal Implants Market Size Report 2032: Market Porter's Five Forces Analysis, M …
DelveInsight's Spinal Implants Market Insights Report 2032 provides the current and forecast market analysis, individual leading Spinal Implants Companies market shares, challenges, Spinal Implants Market Drivers, barriers, trends, and key market Spinal Implants companies in the market.
To read more about the latest highlights related to the Spinal Implants Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/spinal-implants-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Spinal…
Genome Editing Market Size Report 2032: Market Porter's Five Forces Analysis, Ma …
DelveInsight's Genome Editing Market Insights Report 2032 provides the current and forecast market analysis, individual leading Genome Editing Companies market shares, challenges, Genome Editing Market Drivers, barriers, trends, and key market Genome Editing companies in the market.
To read more about the latest highlights related to the Genome Editing Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/genome-editing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Genome Editing Market…
Retinopathy of Prematurity Therapeutics Market: Early-Stage Pipeline and FDA Des …
The Retinopathy of Prematurity treatment market is expected to witness significant growth in the coming years, primarily driven by advancements in diagnostic technologies and the development of novel therapeutics by key players such as Novartis, Regeneron, Bayer, FeliQS Corporation, and Infant Bacterial Therapeutics, among others. This growth trajectory is further supported by the rising awareness about Retinopathy of Prematurity management, improvements in neonatal care units, and increasing focus on preventive…
Chronic Kidney Disease Market Evolution: Novel Drugs, AI Integration, and Combin …
The chronic kidney disease (CKD) treatment market is witnessing robust expansion across the 7MM. This upward trajectory is primarily fueled by increasing disease prevalence, growing aging populations, rising diabetes and hypertension cases, and the emergence of innovative therapies from key chronic kidney disease players including AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Vifor Pharma, Otsuka Pharmaceutical, Reata Pharmaceuticals, Akebia Therapeutics, and Kyowa Kirin, among others, who are actively advancing the CKD…
More Releases for Ovarian
Ovarian Cancer Diagnostics Market Size: 2033 Statistics
The Ovarian Cancer Diagnostics market is expected to grow from an estimated USD 4814.5 million in 2024 to USD 7795.1 million in 2033, at a CAGR of 5.50%.
The ovarian cancer diagnostics market plays a critical role in the early detection and management of ovarian cancer, one of the most common and lethal gynecological cancers worldwide. Ovarian cancer is often diagnosed at an advanced stage due to the lack of noticeable…
Ovarian Cancer Market Size, Future Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ovarian Cancer Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
How deadly is Ovarian Cancer?
Ovarian Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025
Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body.
The global Ovarian Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025,…
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).…
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in…
